Project WISH

UIC Principal Investigator/s: Richard M. Novak M.D and Andrew Trotter, MD, MPH

Study Coordinator: Kristin Boyce, RN

Community Affairs Specialist: Anthony Johnson, MPH

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have s*x with men (MSM and TGW).

The main purpose of this clinical research trial is to see if cabotegravir, an antiretroviral medication can prevent infection with HIV in persons at high risk for HIV infection.

The study will last 1.5 – 3 years and you may be eligible if you are:

18 years of age or older

HIV negative

S*x assigned at birth was male

Gender – male or trans female

Have s*x with men

This study is a double-blind study – all participants receive active medication but neither they nor the study staff will be aware of which medication they are getting. All participants will receive an injection every 2 months and oral tablets that are taken once daily.

Participants will be compensated for their time and will receive regular HIV testing and counseling, condoms and lubricant.

If you are interested in this study – please contact Project WISH to arrange for a phone screen at 312-413-5897

UIC Principal Investigator/s: Richard M. Novak M.D and Stockton Mayer, DO

Study Coordinator: Stephanie Martin, RN, BA

Community Affairs Specialist: Anthony Johnson, MPH

This clinical trial is testing to see if Pitavastatin can prevent heart disease in people with HIV infection who are taking HIV medications. The study is a prospective, double-blind, randomized, placebo-controlled, multicenter phase IV efficacy study. Participants are randomly assigned to either Pitavastatin or placebo. Pitavastatin has been approved by the FDA for a different use, to decrease cholesterol.

You may be eligible for REPRIEVE if you:

Have HIV and are between the ages of 40 and 75

Have been on antiretroviral therapy (ART) for at least 6 months

Have no history of cardiovascular disease

Are not currently taking a statin drug.

UIC Principal Investigator: Richard M. Novak MD

Study Coordinator: Regina Harden

For more information:

www.reprievetrial.org

www.clinicaltrials.gov

If you are interested in this study – please contact Project WISH to arrange for a phone screen at 312-413-5897

We offer three flu season studies, including a clinical trial of a treatment drug, and observational studies of influenza. If you are a UIH provider and have a patient who currently has flu-like symptoms or confirmed influenza, please call Project WISH at 312-413-5897.

UIC Principal Investigator: Richard M. Novak M.D

Study Coordinator: Marla Schwarber, RN